176 related articles for article (PubMed ID: 36328585)
1. Reduced Rate of Disease Flares in Japanese Patients with Systemic Lupus Erythematosus: An Altered Balance between the Use of Glucocorticoids and Immunosuppressants in Recent Decades.
Imaizumi C; Ogura T; Inoue Y; Takakura Y; Katagiri T; Takenaka S; Ito H; Mizushina K; Hirata A; Kameda H
Intern Med; 2022; 61(21):3189-3196. PubMed ID: 36328585
[TBL] [Abstract][Full Text] [Related]
2. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
3. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
[TBL] [Abstract][Full Text] [Related]
4. Disease Flare of Systemic Lupus Erythematosus in Patients With Endstage Renal Disease on Dialysis.
Kim YE; Choi SJ; Lim DH; Kim H; Ahn SM; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
J Rheumatol; 2022 Oct; 49(10):1131-1137. PubMed ID: 35970534
[TBL] [Abstract][Full Text] [Related]
5. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of fetal and maternal pregnancy outcomes in Japanese patients with systemic lupus erythematosus.
Irino K; Arinobu Y; Ayano M; Kawano S; Kimoto Y; Mitoma H; Akahoshi M; Akashi K; Horiuchi T; Niiro H
Lupus; 2021 Sep; 30(10):1637-1643. PubMed ID: 34266321
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.
Sun F; Zhao L; Wang H; Zhang D; Chen J; Wang X; Li T; Ye S
Lupus Sci Med; 2022 May; 9(1):. PubMed ID: 35606018
[TBL] [Abstract][Full Text] [Related]
8. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
[TBL] [Abstract][Full Text] [Related]
9. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
[TBL] [Abstract][Full Text] [Related]
11. The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.
Merrill JT; Immermann F; Whitley M; Zhou T; Hill A; O'Toole M; Reddy P; Honczarenko M; Thanou A; Rawdon J; Guthridge JM; James JA; Sridharan S
Arthritis Rheumatol; 2017 Jun; 69(6):1257-1266. PubMed ID: 28257602
[TBL] [Abstract][Full Text] [Related]
12. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial.
Mathian A; Pha M; Haroche J; Cohen-Aubart F; Hié M; Pineton de Chambrun M; Boutin THD; Miyara M; Gorochov G; Yssel H; Cherin P; Devilliers H; Amoura Z
Ann Rheum Dis; 2020 Mar; 79(3):339-346. PubMed ID: 31852672
[TBL] [Abstract][Full Text] [Related]
13. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
Závada J; Uher M; Svobodová R; Olejárová M; Hušáková M; Ciferská H; Hulejová H; Tomčík M; Šenolt L; Vencovský J
Arthritis Res Ther; 2015 Nov; 17():341. PubMed ID: 26608564
[TBL] [Abstract][Full Text] [Related]
14. Acute acalculous cholecystitis in patients with systemic lupus erythematosus: A unique form of disease flare.
Yang H; Bian S; Xu D; Zhang F; Zhang X
Lupus; 2017 Sep; 26(10):1101-1105. PubMed ID: 28355987
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and risk factors of an emergency department visit in patients with systemic lupus erythematosus.
Nagai Y; Yokogawa N; Shimada K; Sugii S
Rheumatol Int; 2019 Sep; 39(9):1567-1573. PubMed ID: 31309295
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study.
Watanabe H; Yamanaka R; Sada KE; Zeggar S; Katsuyama E; Katsuyama T; Narazaki MT; Tatebe NT; Sugiyama K; Watanabe KS; Wakabayashi H; Kawabata T; Wada J; Makino H
Lupus; 2016 Jan; 25(1):54-60. PubMed ID: 26296361
[TBL] [Abstract][Full Text] [Related]
17. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study.
Fasano S; Coscia MA; Pierro L; Ciccia F
Lupus; 2021 May; 30(6):991-997. PubMed ID: 33709836
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
[TBL] [Abstract][Full Text] [Related]
19. Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative.
Kalunian KC; Kim M; Xie X; Baskaran A; Daly RP; Merrill JT
Eur J Rheumatol; 2016 Mar; 3(1):13-19. PubMed ID: 27708963
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort.
Ugarte-Gil MF; Wojdyla D; Pastor-Asurza CA; Gamboa-Cárdenas RV; Acevedo-Vásquez EM; Catoggio LJ; García MA; Bonfá E; Sato EI; Massardo L; Pascual-Ramos V; Barile LA; Reyes-Llerena G; Iglesias-Gamarra A; Molina-Restrepo JF; Chacón-Díaz R; Alarcón GS; Pons-Estel BA
Lupus; 2018 Apr; 27(4):536-544. PubMed ID: 28857715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
